Invitation OXURION R&D Investor Day – Virtual - 15 October 2020 at 5.30pm CET/ 11.30am ET
08 Ottobre 2020 - 08:00AM
Invitation OXURION R&D Investor Day – Virtual - 15 October 2020
at 5.30pm CET/ 11.30am ET
Invitation OXURION R&D
Investor Day – Virtual
15 October 2020
at 5.30pm CET/ 11.30am ET
Leuven, Belgium, October 8, 2020 – 8 am
CET – Oxurion NV (Euronext Brussels: OXUR), a
biopharmaceutical company developing next generation
standard-of-care therapies for diabetic macular edema (DME), will
host a virtual R&D Investor Day on the
15 October 2020 beginning at 5.30pm CET/ 4.30pm BST/
11.30am ET.
The agenda for the meeting, intended for
investors and analysts, will run as follows:
- Patrik De Haes, M.D., CEO - overview of
Company’s development pipeline and corporate strategy
- Introducing Oxurion’s innovative drug candidates for
next generation DME therapy:
THR-149 (PKal inhibitor) for
DME by Ramin Tadayoni, M.D., Ph.D. Professor of
ophthalmology at University of Paris. He is head of the
Ophthalmology Departments at Lariboisière, St Louis and Rothschild
Foundation Hospitals in Paris, France
THR-687 (pan-RGD integrin
antagonist) by Arshad Khanani, M.D., M.A., Managing
Partner, Director of Clinical Research, Director of Fellowship at
Sierra Eye Associates, and Clinical Associate Professor at the
University of Nevada, Reno, US.
- Grace Chang, M.D., Ph.D., CMO - THR-149 and
THR-687 ongoing and future clinical development
strategies
- Patrik de Haes, M.D., CEO – concluding remarks
and outlook
- Questions & Answers (attended by
Andy De Deene, M.D., CDO and Jean Feyen,
Ph.D., CSO)
There will be a live listen-only webcast of the event.
Please consult the Oxurion website for registration and call
details, or follow this link:
https://www.investis-live.com/oxurion/5f7c2e6ed33b270c005a4f88/ffdl
The meeting is scheduled to last approximately
90mins including the Q&A session.
An on-demand version of the event will also be made available
shortly after the event has finished, this will be accessible via
the same link.
END
For further information please contact:
Oxurion NVWouter Piepers, Global Head of Investor Relations&
Corporate CommunicationsTel: +32 16 75 13 10 / +32 478 33 56
32wouter.piepers@oxurion.com |
Citigate Dewe Rogerson David Dible/ Sylvie Berrebi/ Frazer HallTel:
+44 20 7638 9571oxurion@citigatedewerogerson.com |
About Oxurion
Oxurion (Euronext Brussels: OXUR) is a
biopharmaceutical company developing next generation
standard-of-care therapies to better preserve vision in patients
with diabetic macular edema (DME), the leading cause of vision loss
in diabetic patients worldwide.
Oxurion is building a leading global franchise
in the treatment of DME, based on the successful development of its
two novel therapeutics:
- THR-149, a plasma kallikrein inhibitor being developed as a
potential new standard of care for DME patients who respond
sub-optimally to anti-VEGF therapy.
THR-149 has shown positive topline Phase 1
results for the treatment of DME. The Company is currently
conducting a Phase 2 clinical trial evaluating THR-149 with
DME-patients who previously responded sub-optimally to anti-VEGF
therapy. THR-149 was developed in conjunction with Bicycle
Therapeutics PLC (NASDAQ: BCYC)
- THR-687, is a pan-RGD integrin inhibitor, that is initially
being developed as a potential new standard of care for all DME
patients.
Positive topline results in a Phase 1 clinical
study assessing it as a treatment for DME were announced in January
2020. THR-687 is expected to enter a Phase 2 clinical trial by
mid-2021. THR-687 is an optimized compound derived from a broader
library of integrin inhibitors in-licensed from Galapagos NV
(Euronext & NASDAQ: GLPG).
Oxurion is headquartered in Leuven, Belgium, and is listed on
the Euronext Brussels exchange under the symbol OXUR.
More information is available at
www.oxurion.com.
Important information about
forward-looking statementsCertain statements in this press
release may be considered “forward-looking”. Such forward-looking
statements are based on current expectations, and, accordingly,
entail and are influenced by various risks and uncertainties. The
Company therefore cannot provide any assurance that such
forward-looking statements will materialize and does not assume an
obligation to update or revise any forward-looking statement,
whether as a result of new information, future events or any other
reason. Additional information concerning risks and uncertainties
affecting the business and other factors that could cause actual
results to differ materially from any forward-looking statement is
contained in the Company’s Annual Report. This press release does
not constitute an offer or invitation for the sale or purchase of
securities or assets of Oxurion in any jurisdiction. No
securities of Oxurion may be offered or sold within the United
States without registration under the U.S. Securities Act of 1933,
as amended, or in compliance with an exemption therefrom, and in
accordance with any applicable U.S. state securities laws.
Grafico Azioni Oxurion NV (EU:OXUR)
Storico
Da Feb 2024 a Mar 2024
Grafico Azioni Oxurion NV (EU:OXUR)
Storico
Da Mar 2023 a Mar 2024